/TNYA
TNYA Stock - Tenaya Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.70+4.87%
+$0.03 (+4.87%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+328.3%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TNYA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.69 – $0.71
TARGET (TP)$3.00
STOP LOSS$0.64
RISK/REWARD1:38.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.14
52W High$2.35
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-8,468,000 | $-8,687,000 | $-8,713,000 | $-4,025,000 | $-2,483,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-115,948,000 | $-131,193,000 | $-125,621,000 | $-72,806,000 | $-38,912,000 |
| Net Income | $-111,129,000 | $-124,084,000 | $-123,665,000 | $-72,721,000 | $-38,395,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.31 | $-1.68 | $-2.76 | $-1.69 | $-0.93 |
Company Overview
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$16
Average Target
↑ 2184.1% Upside
Now
$7
Low
$16
Average
$25
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 10th 2024 | William Blair | Initiation | Outperform | - |
| November 30th 2023 | Leerink Partners | Initiation | Outperform | $7 |
| June 15th 2022 | H.C. Wainwright | Initiation | Buy | $25 |
Earnings History & Surprises
TNYABeat Rate
72%
Last 18 quarters
Avg Surprise
+1.9%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
+11.1%
$-0.40vs$-0.45
Q2 24
+7.0%
$-0.40vs$-0.43
Q3 24
+15.0%
$-0.34vs$-0.40
Q4 24
+18.9%
$-0.30vs$-0.37
Q1 25
+9.7%
$-0.28vs$-0.31
Q2 25
-33.3%
$-0.24vs$-0.18
Q3 25
+30.0%
$-0.14vs$-0.20
Q4 25
+20.0%
$-0.12vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.20 | $-0.14 | +30.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.18 | $-0.24 | -33.3% | ✗ MISS |
Q1 2025 | Mar 10, 2025 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.37 | $-0.30 | +18.9% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.40 | $-0.34 | +15.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.43 | $-0.40 | +7.0% | ✓ BEAT |
Q1 2024 | Mar 18, 2024 | $-0.45 | $-0.40 | +11.1% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.47 | $-0.39 | +17.0% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.51 | $-0.45 | +11.8% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.60 | $-0.43 | +28.3% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | $-0.66 | $-0.61 | +7.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.64 | $-0.74 | -15.6% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.75 | $-0.69 | +8.0% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.62 | $-0.75 | -21.0% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-0.57 | $-0.63 | -10.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.81 | $-0.68 | +16.0% | ✓ BEAT |
Q3 2021 | Sep 8, 2021 | $-7.17 | $-13.26 | -84.9% | ✗ MISS |
Q3 2021 | Jul 30, 2021 | — | $-0.48 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $3
➖ NeutralBenzinga•Dec 12, 2025, 04:18 PM
Tenaya Therapeutics shares are trading lower after the company announced the pricing of a $60 million public offering of 50 million units at $1.20 per unit.
📉 NegativeBenzinga•Dec 12, 2025, 02:28 PM
Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8
➖ NeutralBenzinga•Dec 12, 2025, 01:10 PM
Tenaya Therapeutics Prices $60M Underwritten Public Offering Of 50M Units At $1.20 Per Unit
📉 NegativeBenzinga•Dec 12, 2025, 07:34 AM
Tenaya Therapeutics shares are trading lower after the company announced a proposed public offering.
📉 NegativeBenzinga•Dec 11, 2025, 09:24 PM
Tenaya Therapeutics Receives FDA Clearance To Resume MyPEAK‑1 Trial Of TN‑201 For MYBPC3‑Associated Hypertrophic Cardiomyopathy
📈 PositiveBenzinga•Dec 11, 2025, 09:07 PM
Tenaya Therapeutics Reports Interim RIDGE‑1 Trial Data For TN‑401 Gene Therapy In PKP2‑Mutated ARVC
➖ NeutralBenzinga•Dec 11, 2025, 09:05 PM
Tenaya Therapeutics Announces Proposed Public Offering At $0.001/Share; Size Not Disclosed
📉 NegativeBenzinga•Dec 11, 2025, 09:05 PM
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 10, 2025, 08:12 PM
Tenaya Therapeutics shares are trading higher after the company reported Q3 better-than-expected Q3 EPS results.
📈 PositiveBenzinga•Nov 10, 2025, 08:01 PM
Tenaya Therapeutics Q3 EPS $(0.12) Beats $(0.15) Estimate
📈 PositiveBenzinga•Nov 10, 2025, 12:15 PM
Reported Saturday, Tenaya Therapeutics Reports TN-201 Well Tolerated At 3E13 And 6E13 vg/kg With Managed Immunogenicity And No Dose-Limiting Toxicities In MyPEAK-1
📈 PositiveBenzinga•Nov 10, 2025, 09:08 AM
Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial
📉 NegativeSeeking Alpha•Nov 7, 2025, 09:57 PM
Tenaya Therapeutics Says Expects No Impact On TN-201 Timelines From Hold; Says Working To Resolve Clinical Hold And Resume Dosing
➖ NeutralBenzinga•Nov 7, 2025, 09:27 PM
Tenaya Therapeutics shares are trading lower after the company announced the FDA placed a clinical hold on the TN-201 trial.
📉 NegativeBenzinga•Nov 7, 2025, 09:26 PM
FDA Places Clinical Hold On Tenaya Therapeutics' TN-201 Trial, Requests Protocol Amendment For Patient Monitoring And Immunosuppression Management
📉 NegativeBenzinga•Nov 7, 2025, 09:26 PM
Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025
📈 PositiveBenzinga•Nov 4, 2025, 10:39 PM
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Sep 2, 2025, 10:51 AM
Reported Sunday, Tenaya Highlights Urgent Need For Disease-Modifying Approaches In Pediatric MYBPC3-Associated HCM Based On MyClimb Interim Findings
➖ NeutralBenzinga•Sep 2, 2025, 07:42 AM
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Aug 27, 2025, 10:15 AM
Frequently Asked Questions about TNYA
What is TNYA's current stock price?
Tenaya Therapeutics, Inc. (TNYA) is currently trading at $0.70 per share. The stock has moved +4.87% today.
What is the analyst price target for TNYA?
The average analyst price target for TNYA is $3.00, based on 1 analyst.
What sector is Tenaya Therapeutics, Inc. in?
Tenaya Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TNYA's market cap?
Tenaya Therapeutics, Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does TNYA pay dividends?
No, Tenaya Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABEO
Abeona Therapeutics Inc.
$5.11
Mkt Cap: $0.3B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to TNYA for comparison